TRIAD3 Inhibitors
The chemical class of TRIAD3 inhibitors constitutes a diverse array of compounds strategically designed to modulate the regulation and function of TRIAD3, an E3 ubiquitin ligase crucial for cellular homeostasis. TRIAD3, also known as RNF216, is recognized for its involvement in ubiquitin-mediated protein degradation, particularly in the context of antiviral responses and cellular stress pathways. PD 98059, classified as a mitogen-activated protein kinase (MEK) inhibitor, perturbs the mitogen-activated protein kinase (MAPK) pathway. Its indirect influence on TRIAD3 stems from alterations in downstream targets within this pivotal signaling cascade. Likewise, Wortmannin, a phosphoinositide 3-kinase (PI3K) inhibitor, intervenes in the PI3K/AKT pathway, offering indirect regulation of TRIAD3 through modifications in key signaling events. These inhibitors shed light on the intricate signaling networks that intricately regulate TRIAD3 function, emphasizing the interplay between ubiquitin-mediated degradation and cellular signaling pathways.
Expanding the spectrum, 5-Fluorouracil, Dasatinib, and Cisplatin, impacting nucleotide synthesis, tyrosine kinase activity, and DNA synthesis, respectively, contribute to the indirect modulation of TRIAD3. Their influence on cellular processes connected to TRIAD3 regulation showcases the multifaceted nature of the interactions involved in maintaining TRIAD3 homeostasis. Furthermore, SB203580, Rapamycin, and BAY 11-7082 disrupt the MAPK, mammalian target of rapamycin (mTOR), and nuclear factor-kappa B (NF-κB) pathways, respectively. Through indirect regulation, these compounds intricately influence TRIAD3 by altering signaling cascades associated with cellular stress responses and inflammatory pathways. The chemical class of TRIAD3 inhibitors thus unfolds as a spectrum of compounds, each wielding distinct mechanisms of action. Their convergence on intricate cellular pathways signifies a concerted effort to impact TRIAD3 regulation and function. This comprehensive understanding provides a foundation for exploring the dynamic interplay between TRIAD3 and cellular signaling networks, unveiling potential avenues for further investigation into the regulation of TRIAD3 within the intricate landscape of cellular processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059, a MEK inhibitor, disrupts the MAPK pathway. By inhibiting MEK, it influences downstream targets and modulates cellular responses. This indirect modulation of TRIAD3 may occur through altered MAPK signaling, impacting TRIAD3 regulation or function within this pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, a PI3K inhibitor, disrupts the PI3K/AKT pathway. By inhibiting PI3K, it influences downstream signaling events. This interference in the PI3K/AKT pathway may indirectly regulate TRIAD3, as the protein is connected to cellular processes influenced by PI3K signaling, providing a potential indirect inhibitory effect. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
5-Fluorouracil, a thymidylate synthase inhibitor, disrupts nucleotide synthesis. By inhibiting thymidylate synthase, it modulates DNA replication. This indirect modulation of TRIAD3 may occur through altered DNA replication processes, impacting TRIAD3 expression or function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, disrupts the JNK signaling pathway. By inhibiting JNK, it influences downstream targets. This interference in the JNK pathway may indirectly regulate TRIAD3, as the protein is involved in cellular processes impacted by JNK signaling, providing a potential indirect inhibitory effect. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082, an NF-κB inhibitor, interferes with the NF-κB signaling pathway. By modulating NF-κB activity, it indirectly influences TRIAD3, as the protein's expression can be regulated by NF-κB. The inhibition of NF-κB may lead to altered expression levels of TRIAD3, impacting its cellular functions indirectly. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib, a Src/Abl inhibitor, perturbs tyrosine kinase activity. By inhibiting Src and Abl kinases, it disrupts signaling cascades, potentially influencing cellular processes linked to TRIAD3. The indirect modulation of TRIAD3 might occur through alterations in tyrosine phosphorylation events or cross-talk with pathways where Src and Abl kinases are implicated. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580, a p38 MAP kinase inhibitor, disrupts the MAPK signaling cascade. By inhibiting p38, it affects downstream targets. This interference in the MAPK pathway may indirectly regulate TRIAD3, as the protein is implicated in certain cellular responses influenced by MAPK signaling, providing a potential indirect inhibitory effect. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, disrupts the mTOR signaling pathway. Through mTOR inhibition, it influences downstream cellular processes. This interference in the mTOR pathway may indirectly regulate TRIAD3, as the protein is implicated in cellular responses affected by mTOR signaling, providing a potential indirect inhibitory effect. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Cisplatin, a DNA crosslinking agent, interferes with DNA synthesis. By forming DNA adducts, it modulates DNA structure. This indirect modulation of TRIAD3 may occur through altered DNA integrity, impacting TRIAD3 expression or function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a PI3K inhibitor, disrupts the PI3K/AKT pathway. By inhibiting PI3K, it influences downstream signaling events. This interference in the PI3K/AKT pathway may indirectly regulate TRIAD3, as the protein is connected to cellular processes influenced by PI3K signaling, providing a potential indirect inhibitory effect. | ||||||